AAPL   380.57 (+2.11%)
MSFT   211.24 (+1.44%)
FB   240.88 (+0.01%)
GOOGL   1,509.13 (+1.29%)
AMZN   3,049.83 (+1.66%)
NVDA   403.90 (+2.29%)
BABA   251.61 (+6.38%)
MU   49.63 (+1.10%)
GE   6.77 (+0.00%)
TSLA   1,391.00 (+0.08%)
AMD   52.79 (-0.28%)
ACB   12.29 (-1.05%)
F   6.09 (-0.49%)
GILD   76.46 (+0.05%)
DIS   114.03 (+0.35%)
BAC   22.83 (-0.78%)
NFLX   499.99 (+1.38%)
AAPL   380.57 (+2.11%)
MSFT   211.24 (+1.44%)
FB   240.88 (+0.01%)
GOOGL   1,509.13 (+1.29%)
AMZN   3,049.83 (+1.66%)
NVDA   403.90 (+2.29%)
BABA   251.61 (+6.38%)
MU   49.63 (+1.10%)
GE   6.77 (+0.00%)
TSLA   1,391.00 (+0.08%)
AMD   52.79 (-0.28%)
ACB   12.29 (-1.05%)
F   6.09 (-0.49%)
GILD   76.46 (+0.05%)
DIS   114.03 (+0.35%)
BAC   22.83 (-0.78%)
NFLX   499.99 (+1.38%)
AAPL   380.57 (+2.11%)
MSFT   211.24 (+1.44%)
FB   240.88 (+0.01%)
GOOGL   1,509.13 (+1.29%)
AMZN   3,049.83 (+1.66%)
NVDA   403.90 (+2.29%)
BABA   251.61 (+6.38%)
MU   49.63 (+1.10%)
GE   6.77 (+0.00%)
TSLA   1,391.00 (+0.08%)
AMD   52.79 (-0.28%)
ACB   12.29 (-1.05%)
F   6.09 (-0.49%)
GILD   76.46 (+0.05%)
DIS   114.03 (+0.35%)
BAC   22.83 (-0.78%)
NFLX   499.99 (+1.38%)
AAPL   380.57 (+2.11%)
MSFT   211.24 (+1.44%)
FB   240.88 (+0.01%)
GOOGL   1,509.13 (+1.29%)
AMZN   3,049.83 (+1.66%)
NVDA   403.90 (+2.29%)
BABA   251.61 (+6.38%)
MU   49.63 (+1.10%)
GE   6.77 (+0.00%)
TSLA   1,391.00 (+0.08%)
AMD   52.79 (-0.28%)
ACB   12.29 (-1.05%)
F   6.09 (-0.49%)
GILD   76.46 (+0.05%)
DIS   114.03 (+0.35%)
BAC   22.83 (-0.78%)
NFLX   499.99 (+1.38%)
Log in

NASDAQ:MGTAMagenta Therapeutics Stock Price, Forecast & News

$8.91
+0.08 (+0.91 %)
(As of 07/8/2020 11:02 AM ET)
Add
Compare
Today's Range
$8.86
Now: $8.91
$9.10
50-Day Range
$7.41
MA: $9.16
$10.56
52-Week Range
$5.76
Now: $8.91
$16.19
Volume8,275 shs
Average Volume480,947 shs
Market Capitalization$351.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.84
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
Magenta Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTA
CUSIPN/A
CIKN/A
Phone857-242-0170

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.62 per share

Profitability

Net Income$-76,770,000.00

Miscellaneous

Employees59
Market Cap$351.77 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive MGTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTA and its competitors with MarketBeat's FREE daily newsletter.

Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

How has Magenta Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MGTA stock has decreased by 2.7% and is now trading at $8.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Magenta Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Magenta Therapeutics.

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Magenta Therapeutics.

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics Inc (NASDAQ:MGTA) posted its earnings results on Thursday, May, 7th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.09. View Magenta Therapeutics' earnings history.

What price target have analysts set for MGTA?

4 analysts have issued twelve-month price objectives for Magenta Therapeutics' shares. Their forecasts range from $15.00 to $22.00. On average, they expect Magenta Therapeutics' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 113.2% from the stock's current price. View analysts' price targets for Magenta Therapeutics.

Has Magenta Therapeutics been receiving favorable news coverage?

Media coverage about MGTA stock has been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Magenta Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Magenta Therapeutics.

Are investors shorting Magenta Therapeutics?

Magenta Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,020,000 shares, an increase of 12.7% from the June 15th total of 904,700 shares. Based on an average daily trading volume, of 187,800 shares, the days-to-cover ratio is presently 5.4 days. Currently, 4.7% of the shares of the company are sold short. View Magenta Therapeutics' Current Options Chain.

Who are some of Magenta Therapeutics' key competitors?

What other stocks do shareholders of Magenta Therapeutics own?

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the following people:
  • Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 48)
  • Mr. Michael P. Cooke, Chief Scientific Officer (Age 57)
  • Ms. Alison Lawton, Board Advisor (Age 58)
  • Mr. Jason Ryan, Chief Operating & Financial Officer (Age 45)
  • Ms. Manisha Pai, VP of Investor Relations & Communications

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $8.91.

How big of a company is Magenta Therapeutics?

Magenta Therapeutics has a market capitalization of $351.77 million. The company earns $-76,770,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is www.magentatx.com.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.